Why MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 6.45%
As of Wednesday, March 04, MIRA Pharmaceuticals, Inc.’s MIRA share price has dipped by 6.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Commentary & Analysis
Why MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 5.81%
As of Tuesday, March 03, MIRA Pharmaceuticals, Inc.’s MIRA share price has dipped by 5.81%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 13.39%
As of Monday, March 02, MIRA Pharmaceuticals, Inc.’s MIRA share price has dipped by 13.39%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Up 5.69%
As of Tuesday, February 24, MIRA Pharmaceuticals, Inc.’s MIRA share price has surged by 5.69%, which has investors questioning if this is right time to sell.Jenna Brashear
Why MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 8.71%
As of Friday, February 20, MIRA Pharmaceuticals, Inc.’s MIRA share price has dipped by 8.71%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MIRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $32.5 | $609.5 | 13% |
|
| Shares Out (Mil) | 42.0 | 43.4 | 43% |
|
| Institutional Ownership | 34.4% | 83.9% | 14% |
|
| Float (Mil) | 35.0 | 45.7 | 39% |
|
| Beta | 1.55 | 0.73 | 84% |
|
| Avg Daily Volume (000s) | 3,125 | 309 | 89% |
|
| Price Change (52-week) |
(49.1%) | 64.9% | 16% |
|
| Growth | MIRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (153.2%) | (1.6%) | 1% |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MIRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($11) | 29% |
|
| EPS (TTM) | ($0.862) | ($0.700) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($7) | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $24 | $525 | 12% |
|
| Valuation | MIRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.07 | 2.61 | 74% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MIRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 0.8% | na |
|
| ROA | (209.0%) | (22.7%) | 2% |
|
| ROE | (217.1%) | (22.8%) | 4% |
|
| Liabilities to Assets | 0.5% | 33.1% | 0% |
|
| F-Score | 3 | 3 | 18% |
|
MIRA Pharmaceuticals, Inc. did not pass any screens on 9/11/2026.
